Research programme: inflammation therapeutics - Neoloch
Latest Information Update: 04 Jul 2016
At a glance
- Originator Neoloch
- Class Peptides
- Mechanism of Action Interferon beta modulators; Interleukin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Multiple sclerosis
Most Recent Events
- 04 Jul 2016 Preclinical trials in Multiple sclerosis in Denmark (Parenteral)
- 04 Jul 2016 Preclinical trials in Autoimmune disorders in Denmark (Parenteral)